Dr. Reddy's Laboratories Ltd ADR (RDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2026 | 03-2025 | 03-2024 | 03-2023 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 479,866 | 671,000 | 668,000 | 548,000 | 311,000 |
| Depreciation Amortization | 232,837 | 200,000 | 178,000 | 154,000 | 156,000 |
| Income taxes - deferred | 139,566 | 229,000 | 194,000 | 186,000 | 115,000 |
| Accounts receivable | -75,959 | -120,000 | -97,000 | -70,000 | -224,000 |
| Accounts payable and accrued liabilities | 31,527 | 4,000 | 42,000 | N/A | 58,000 |
| Other Working Capital | -131,487 | -350,000 | -242,000 | -96,000 | -183,000 |
| Other Operating Activity | -35,019 | -89,000 | -198,000 | -6,000 | 137,000 |
| Operating Cash Flow | $641,332 | $545,000 | $545,000 | $716,000 | $370,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -260,092 | -316,000 | -184,000 | -137,000 | -188,000 |
| Net Acquisitions | -35,618 | -622,000 | N/A | N/A | -4,000 |
| Purchase Of Investment | -528,490 | -2,983,000 | -1,747,000 | -1,657,000 | -1,173,000 |
| Sale Of Investment | 221,503 | 3,273,000 | 1,557,000 | 1,372,000 | 1,025,000 |
| Purchase Sale Intangibles | -154,787 | -72,000 | -131,000 | -92,000 | -19,000 |
| Other Investing Activity | -137,600 | -34,000 | -109,000 | -81,000 | -8,000 |
| Investing Cash Flow | $-740,297 | $-682,000 | $-483,000 | $-503,000 | $-348,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 228,904 | 287,000 | 66,000 | -236,000 | 46,000 |
| Debt Issued | N/A | N/A | 46,000 | N/A | N/A |
| Debt Repayment | -11 | N/A | -46,000 | N/A | N/A |
| Common Stock Issued | 4,486 | 85,000 | 10,000 | 2,000 | 4,000 |
| Common Stock Repurchased | N/A | -16,000 | N/A | 3,000 | N/A |
| Dividend Paid | -75,247 | -78,000 | -80,000 | -61,000 | -55,000 |
| Other Financing Activity | -64,455 | -56,000 | -41,000 | -35,000 | -27,000 |
| Financing Cash Flow | $93,677 | $222,000 | $-45,000 | $-327,000 | $-32,000 |
| Exchange Rate Effect | 14,046 | 1,000 | -1,000 | 3,000 | 10,000 |
| Beginning Cash Position | 164,901 | 85,000 | 69,000 | 181,000 | 195,000 |
| End Cash Position | 173,658 | 171,000 | 85,000 | 70,000 | 196,000 |
| Net Cash Flow | $8,758 | $86,000 | $16,000 | $-111,000 | $1,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 641,332 | 545,000 | 545,000 | 716,000 | 370,000 |
| Capital Expenditure | -263,584 | -322,000 | -197,000 | -138,000 | -193,000 |
| Free Cash Flow | 377,748 | 223,000 | 348,000 | 578,000 | 177,000 |